-
Development and Validation of a Case Identification Algorithm for Hand Trauma Patients Using Health Administrative Data and the Epidemiology of Hand Trauma in a Universal Healthcare System
Sep 9, 2025, 16:22 PM -
Receipt of Biomarker Testing in Non-Small Cell Lung Cancer: Using Real-World Data to Identify Testing Gaps and Treatment Characteristics
Sep 9, 2025, 16:22 PM -
Impact of Different CV Risk Estimation Methods on Cost-Effectiveness Analysis
Sep 9, 2025, 16:22 PM -
The Role of a Functional Clinical Staff in Guiding High-Cost Drug and Novel Technology Decision Making: Experience From a Latin American Oncology Clinic
Sep 9, 2025, 16:22 PM -
Pillcam COLON 2 for Investigation of the COLON Through Direct Visualization: A Systematic Review
Sep 9, 2025, 16:22 PM -
Treatment Patterns, Inadequate Disease Control, and Burden/Unmet Need Among Adult Patients With Moderate-to-Severe Atopic Dermatitis: Results From the Adelphi Real-World Disease Specific Program
Sep 9, 2025, 16:22 PM -
Evaluating the Performance of an Artificial Intelligence A-Powered Tool for Assessing Quality of Published Economic Evaluations: A Comparison With Human Reviewers Using the Drummond Checklist
Sep 9, 2025, 16:22 PM -
Innovation in Off-Patent Competitive Environment: Key Learnings From Successes and Failures
Sep 9, 2025, 16:22 PM -
HTA League of Nations: Which Bodies Were Most Likely to Approve Submissions and for What Disease Areas?
Sep 9, 2025, 16:22 PM -
Confidential Prices in NICE Health Technology Assessment: How Common Are They?
Sep 9, 2025, 16:22 PM -
Bridging the Uncertainty: Cancer Drugs Fund Entry and Exit Outcomes Over Three Years
Sep 9, 2025, 16:22 PM -
Analysis of Pros Included in the HTA Assessment of Conditionally Approved Oncology Drugs in the UK, Italy, and Germany
Sep 9, 2025, 16:22 PM -
Who Speaks For Europe? A Country-Level Analysis Of Representation And Expertise In EU Health Technology Assessment Joint Bodies
Sep 9, 2025, 16:22 PM -
Value of Patient-Reported Outcomes Data in Food and Drug Administration Labeling of Oncology Drugs to Payers in the United States
Sep 9, 2025, 16:22 PM -
Care Now, Pay Later (CNPL): Evaluating the Budgetary and Access Implications of a Novel Financing Model for Inclisiran in Atherosclerotic Cardiovascular Disease (ASCVD) Patients in India
Sep 9, 2025, 16:22 PM -
Spillover Effects on Informal and Family Caregivers' Utility: A Systematic Literature Review
Sep 9, 2025, 16:22 PM -
Hospital Mortality in Germany Analysis of German Hospital Data From 2000 to 2019
Sep 9, 2025, 16:22 PM -
The Impact of Delaying Access to Innovative Therapies in Emerging Markets for Chronic Lymphocytic Leukemia: A Modeling Study
Sep 9, 2025, 16:22 PM -
Assessing Patient Access to Psoriasis Treatments in Central, South, and Eastern European Countries: Insights and Disparities?
Sep 9, 2025, 16:22 PM -
Health Utility and Indirect Costs of Neuromuscular Disease Through a Patient-Centered Lens: A National Patient and Caregiver Survey
Sep 9, 2025, 16:22 PM
